Anebulo Pharmaceuticals, Inc. ANEB
We take great care to ensure that the data presented and summarized in this overview for Anebulo Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ANEB
View all-
22 Nw, LP Seattle, WA5.37MShares$14.1 Million15.16% of portfolio
-
Lvw Advisors, LLC642KShares$1.69 Million0.32% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT511KShares$1.34 Million0.09% of portfolio
-
Morgan Stanley New York, NY399KShares$1.05 Million0.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX158KShares$415,1770.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA153KShares$403,6310.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA25.3KShares$66,4150.0% of portfolio
-
Geode Capital Management, LLC Boston, MA22.8KShares$59,9030.0% of portfolio
-
Boothbay Fund Management, LLC New York, NY19KShares$49,9120.0% of portfolio
-
Tower Research Capital LLC (Trc) New York, NY5.14KShares$13,5120.0% of portfolio
Latest Institutional Activity in ANEB
Top Purchases
Top Sells
About ANEB
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Insider Transactions at ANEB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2023
|
Aron R. English Director |
BUY
Bona fide gift
|
Indirect |
300,000
+5.29%
|
-
|
|
Dec 18
2023
|
Aron R. English Director |
SELL
Bona fide gift
|
Indirect |
300,000
-100.0%
|
-
|
|
Nov 13
2023
|
Aron R. English Director |
BUY
Grant, award, or other acquisition
|
Indirect |
300,000
+50.0%
|
-
|
|
Sep 28
2022
|
Aron R. English Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,703,577
+25.16%
|
$3,407,154
$2.81 P/Share
|
|
Dec 17
2021
|
Aron R. English Director |
BUY
Open market or private purchase
|
Indirect |
400
+0.01%
|
$2,400
$6.59 P/Share
|
|
Dec 14
2021
|
Aron R. English Director |
BUY
Open market or private purchase
|
Indirect |
412
+0.01%
|
$2,060
$5.89 P/Share
|
|
Dec 03
2021
|
Aron R. English Director |
BUY
Open market or private purchase
|
Indirect |
4,500
+0.13%
|
$22,500
$5.93 P/Share
|
|
Dec 02
2021
|
Aron R. English Director |
BUY
Open market or private purchase
|
Indirect |
13,836
+0.41%
|
$69,180
$5.3 P/Share
|
|
May 06
2021
|
Aron R. English Director |
BUY
Grant, award, or other acquisition
|
Indirect |
714,286
+17.6%
|
$5,000,002
$7.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 300K shares |
|---|---|
| Bona fide gift | 300K shares |
| Bona fide gift | 300K shares |
|---|